ReutersIgor the Siberian tiger gets stem-cell hip treatment in HungaryReutersSZEGED, Hungary (Reuters) – Igor, a Siberian tiger in a Hungarian zoo, received stem-cell joint treatment on Wednesday which doctors hoped would help heal its hip and allow it… Continue reading
R & D MagazineAACR 2018: “Universal” CAR T-Cell Product Could Make Treatment More AccessibleR & D MagazineFT819, an off-the-shelf, T-cell receptor (TCR)-less CD19 CAR T-cell product—created from cells of a healthy donor rather than the patient themselv… Continue reading
Targeted OncologyMutation Burden Predictive of First-Line Immunotherapy Response in NSCLCTargeted OncologyIn an updated analysis of CheckMate-586, investigators found that tumor mutational burden (TMB) identified patients with non–small cell lung cance… Continue reading
FierceBiotech |
Solid Bio clears partial hold, but DMD gene therapy trial is still on hold
FierceBiotech Solid Biosciences halted the phase 1/2 trial of its Duchenne muscular dystrophy treatment in March, after being hit with a pair of FDA clinical holds. The biotech has now fixed the manufacturing issue that led to a partial clinical hold on the study … Full FDA letter in hand, Solid Bio says it’s working to reverse clinical hold on its DMD gene therapyEndpoints News Solid Biosciences Provides Update On SGT-001 Clinical Development Program For Duchenne Muscular DystrophyGlobeNewswire (press release) Solid Bio receives FDA Clinical Hold letter related to DMD candidate SCT-001, manufacturing questions addressedSeeking Alpha StreetInsider.com all 9 news articles » |
EurekAlert (press release) |
New light shed on how bone marrow niches keep stem cells thriving
EurekAlert (press release) “In the absence of Ebf3, the stem cell population dropped fairly sharply, consistent with CAR cells playing a major role HSC regulation,” Seike adds. “What we didn’t expect was the impact the removal would have on the shape of the niche itself. We … |